Seegene Management

Management Kriterienprüfungen 0/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Jong-Yoon Chun

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	no data
Eigentum des Geschäftsführers	25.4%
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	keine Daten

Jüngste Management Updates

Recent updates

Analyseartikel • Mar 27

Seegene, Inc. (KOSDAQ:096530) Shares Fly 25% But Investors Aren't Buying For Growth

Seegene, Inc. ( KOSDAQ:096530 ) shareholders have had their patience rewarded with a 25% share price jump in the last...

Analyseartikel • Jan 08

Seegene, Inc. (KOSDAQ:096530) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Seegene, Inc. ( KOSDAQ:096530 ) shareholders would be excited to see that the share price has had a great month...

Analyseartikel • Nov 22

Investors Shouldn't Be Too Comfortable With Seegene's (KOSDAQ:096530) Earnings

Despite posting some strong earnings, the market for Seegene, Inc.'s ( KOSDAQ:096530 ) stock hasn't moved much. Our...

Analyseartikel • Nov 12

Is Seegene (KOSDAQ:096530) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Analyseartikel • Aug 10

Seegene, Inc.'s (KOSDAQ:096530) Share Price Boosted 44% But Its Business Prospects Need A Lift Too

Seegene, Inc. ( KOSDAQ:096530 ) shareholders would be excited to see that the share price has had a great month...

Analyseartikel • Mar 07

A Look At The Fair Value Of Seegene, Inc. (KOSDAQ:096530)

Key Insights Seegene's estimated fair value is ₩22,248 based on 2 Stage Free Cash Flow to Equity Current share price of...

Analyseartikel • May 06

Is Seegene, Inc. (KOSDAQ:096530) Trading At A 32% Discount?

Does the May share price for Seegene, Inc. ( KOSDAQ:096530 ) reflect what it's really worth? Today, we will estimate...

Geschäftsführer

Jong-Yoon Chun (69 yo)

no data

Amtszeit

Dr. Jong-Yoon Chun founded Seegene, Inc. in 2000 and serves as its Chief Executive Officer and Chief Technology Officer. Dr. Chun serves as Director at Seegene, Inc. and serves as its Chairman of the Board...

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/08/10 16:51
Aktienkurs zum Tagesende	2026/08/10 00:00
Gewinne	2026/03/31
Jährliche Einnahmen	2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Seegene, Inc. wird von 15 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
David Lee	CLSA
Jonghyun Park	DAOL Investment & Securities Co., Ltd.
Jinhee Kwak	Eugene Investment & Securities Co Ltd.

Seegene Management

Management Kriterienprüfungen 0/4

Wichtige Informationen

Jüngste Management Updates

Seegene, Inc., Annual General Meeting, Mar 27, 2026

Seegene, Inc., Annual General Meeting, Mar 28, 2025

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Seegene Inc. Announces Comprehensive Syndromic PCR-Based Testing Approach For Reproductive Tract Infections

Seegene Launches Global Million Clinical Study to Establish Clinical Evidence for Comprehensive Syndromic PCR Testing

Seegene Launches Global Million Clinical Study to Shape New Disease-Specific Testing Standards

Upcoming dividend of ₩200 per share

Seegene Launches Allplex MDRO Assay Under IVDR

Consensus EPS estimates increase by 52%, revenue downgraded

Investor sentiment improves as stock rises 15%

Seegene's (KOSDAQ:096530) Performance Is Even Better Than Its Earnings Suggest

Full year 2025 earnings: EPS misses analyst expectations

Seegene, Inc., Annual General Meeting, Mar 27, 2026

Price target decreased by 8.1% to ₩39,500

Seegene, Inc. to Report Q4, 2025 Results on Feb 25, 2026

Upcoming dividend of ₩200 per share

Seegene (KOSDAQ:096530) Seems To Use Debt Rather Sparingly

Consensus EPS estimates fall by 34%

Seegene Inc. Unveils CURECA™? and STAgora™? At ADLM 2025, Advancing the Next Stage of Diagnostics

Does Seegene (KOSDAQ:096530) Have A Healthy Balance Sheet?

Upcoming dividend of ₩200 per share

Price target increased by 8.9% to ₩43,000

Seegene, Inc. (KOSDAQ:096530) Shares Fly 25% But Investors Aren't Buying For Growth

Seegene Inc. Announces Development of CURECA, A Next-Generation Fully Automated PCR Solution Featuring Customizable Pre- Treatment Automation

Seegene, Inc., Annual General Meeting, Mar 28, 2025

New major risk - Revenue and earnings growth

Seegene, Inc. (KOSDAQ:096530) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Investor sentiment improves as stock rises 22%

Upcoming dividend of ₩200 per share

New major risk - Financial data availability

Investors Shouldn't Be Too Comfortable With Seegene's (KOSDAQ:096530) Earnings

Third quarter 2024 earnings released: EPS: ₩36.00 (vs ₩101 loss in 3Q 2023)

Is Seegene (KOSDAQ:096530) Using Too Much Debt?

Seegene, Inc.(KOSDAQ:A096530) dropped from FTSE All-World Index (USD)

Upcoming dividend of ₩200 per share

Investor sentiment deteriorates as stock falls 16%

Seegene, Inc. Develops mpox PCR Test Assays following the WHO Global Health Emergency Declaration

New minor risk - Share price stability

Seegene, Inc.'s (KOSDAQ:096530) Share Price Boosted 44% But Its Business Prospects Need A Lift Too

Now 28% overvalued after recent price rise

Upcoming dividend of ₩200 per share

Now 20% overvalued

Upcoming dividend of ₩200 per share

Full year 2023 earnings: EPS and revenues exceed analyst expectations

A Look At The Fair Value Of Seegene, Inc. (KOSDAQ:096530)

New minor risk - Share price stability

Now 28% overvalued after recent price rise

Upcoming dividend of ₩200 per share at 3.5% yield

Price target decreased by 8.8% to ₩25,000

New minor risk - Share price stability

Upcoming dividend of ₩200 per share at 3.7% yield

Consensus EPS estimates fall from profit to ₩18.00 loss

New minor risk - Share price stability

Investor sentiment improves as stock rises 18%

Seegene Inc. Unveils Solutions to Popularize Molecular Diagnostics At 2023 AACC

Seegene, Inc. (KOSDAQ:A096530) announces an Equity Buyback for KRW 30,000 million worth of its shares.

Upcoming dividend of ₩200 per share at 3.7% yield

Upcoming dividend of ₩200 per share at 3.1% yield

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 21%

Upcoming dividend of ₩400 per share

Investor sentiment deteriorated over the past week

Price target decreased to ₩38,667

Less than half of directors are independent

Seegene, Inc. (KOSDAQ:A096530) announces an Equity Buyback for KRW 50,000 million worth of its shares.

Upcoming dividend of ₩200 per share

Consensus revenue estimates fall by 24%

Now 20% undervalued

Investor sentiment improved over the past week

Seegene, Inc. to Pave Way for PCR Testing At Local Clinics with EU-Approved Multiplex Test and Fully Automated PCR Solution

Seegene Inc. Develops PCR Test to Detect Monkeypox Virus

Upcoming dividend of ₩400 per share

Now 24% undervalued after recent price drop

Price target decreased to ₩71,500